Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban
Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated an...
| Permalink: | http://skupni.nsk.hr/Record/nsk.NSK01001102500/Details |
|---|---|
| Matična publikacija: |
Biochemia medica (Online) 30 (2020), 1 ; str. 74-82 |
| Glavni autori: | Margetić, Sandra (Author), Ćelap, Ivana, Delić-Brkljačić, Diana, Pavlović, Nikola, liječnik, Šupraha Goreta, Sandra, Kobasić, Ivana, Lovrenčić-Huzjan, Arijana, Bašić Kes, Vanja |
| Vrsta građe: | e-članak |
| Jezik: | eng |
| Predmet: | |
| Online pristup: |
https://doi.org/10.11613/BM.2020.010702 Biochemia medica (Online) Hrčak |
| LEADER | 03680naa a22004454i 4500 | ||
|---|---|---|---|
| 001 | NSK01001102500 | ||
| 003 | HR-ZaNSK | ||
| 005 | 20210719092558.0 | ||
| 006 | m d | ||
| 007 | cr|||||||||||| | ||
| 008 | 210527s2020 ci d |o |0|| ||eng | ||
| 024 | 7 | |2 doi |a 10.11613/BM.2020.010702 | |
| 035 | |a (HR-ZaNSK)001102500 | ||
| 040 | |a HR-ZaNSK |b hrv |c HR-ZaNSK |e ppiak | ||
| 041 | 0 | |a eng |b eng | |
| 042 | |a croatica | ||
| 044 | |a ci |c hr | ||
| 080 | 1 | |a 61 |2 2011 | |
| 080 | 1 | |a 577 |2 2011 | |
| 100 | 1 | |a Margetić, Sandra |4 aut | |
| 245 | 1 | 0 | |a Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban |h [Elektronička građa] : |b possibilities and limitations / |c Sandra Margetić, Ivana Ćelap, Diana Delić Brkljačić, Nikola Pavlović, Sandra Šupraha Goreta, Ivana Kobasić, Arijana Lovrenčić-Huzjan, Vanja Bašić Kes. |
| 300 | |b Graf. prikazi. | ||
| 504 | |a Bibliografija: 26 jed. | ||
| 504 | |a Summary. | ||
| 520 | |a Clinical application of rivaroxaban and apixaban does not require therapeutic monitoring. Commercial anti-activated factor X (anti-FXa) inhibition methods for all anti-FXa drugs are based on the same principle, so there are attempts to evaluate potential clinical application of heparin-calibrated anti-FXa assay as an alternative method for direct FXa inhibitors. We aimed to evaluate relationship between anti-FXa methods calibrated with low molecular weight heparin (LMWH) and with drug specific calibrators, and to determine whether commercial LMWH anti-FXa assay can be used to exclude the presence of clinically relevant concentrations of rivaroxaban and apixaban. Materials and methods: Low molecular weight heparin calibrated reagent (Siemens Healthineers, Marburg, Germany) was used for anti-FXa activity measurement. Innovance heparin (Siemens Healthineers, Marburg, Germany) calibrated with rivaroxaban and apixaban calibrators (Hyphen BioMed, Neuville-sur-Oise, France) was used for quantitative determination of FXa inhibitors. Results: Analysis showed good agreement between LMWH calibrated and rivaroxaban calibrated activity (κ = 0.76) and very good agreement with apixaban calibrated anti-Xa activity (κ = 0.82), respectively. Low molecular weight heparin anti-FXa activity cut-off values of 0.05 IU/mL and 0.1 IU/mL are suitable for excluding the presence of clinically relevant concentrations (<30 ng/mL) of rivaroxaban and apixaban, respectively. Concentrations above 300 ng/mL exceeded upper measurement range for LMWH anti-FXa assay and cannot be determined by this method. Conclusion: Low molecular weight heparin anti-FXa assay can be used in emergency clinical conditions for ruling out the presence of clinically relevant concentrations of rivaroxaban and apixaban. However, use of LMWH anti-FXa assay is not appropriate for their quantitative determination as an interchangeable method. | ||
| 653 | 0 | |a Rivaroksaban |a Apiksaban |a Heparin |a Inhibitori faktora Xa | |
| 700 | 1 | |a Ćelap, Ivana |4 aut | |
| 700 | 1 | |a Delić-Brkljačić, Diana |4 aut | |
| 700 | 1 | |a Pavlović, Nikola, |c liječnik |4 aut | |
| 700 | 1 | |a Šupraha Goreta, Sandra |4 aut | |
| 700 | 1 | |a Kobasić, Ivana |4 aut | |
| 700 | 1 | |a Lovrenčić-Huzjan, Arijana |4 aut | |
| 700 | 1 | |a Bašić Kes, Vanja |4 aut | |
| 773 | 0 | |t Biochemia medica (Online) |x 1846-7482 |g 30 (2020), 1 ; str. 74-82 |w nsk.(HR-ZaNSK)000655372 | |
| 981 | |b Be2020 |b B03/20 | ||
| 998 | |b dalo2107 | ||
| 856 | 4 | 0 | |u https://doi.org/10.11613/BM.2020.010702 |
| 856 | 4 | 0 | |u https://www.biochemia-medica.com/en/journal/30/1/10.11613/BM.2020.010702 |y Biochemia medica (Online) |
| 856 | 4 | 1 | |y Digitalna.nsk.hr |
| 856 | 4 | 0 | |u https://hrcak.srce.hr/234052 |y Hrčak |